MedPacto CEO Kim Sung-jin Introduces 'Bactosertib' Treatment Effect at Bio Korea
[Asia Economy Reporter Lee Gwan-joo] MedPacto announced on the 11th that CEO Kim Sung-jin will introduce the therapeutic effects of the anticancer new drug 'Vactosertib' at 'Bio Korea 2022,' held from the 11th to the 13th at COEX in Seoul.
MedPacto CEO Kim Sung-jin is scheduled to speak as an invited speaker at the session titled "Immune Checkpoint Inhibitors: A New Horizon in Cancer Treatment," presenting on "The Combination Therapy Effects of Vactosertib with Various Anticancer Drugs."
CEO Kim will explain the anticancer effects of Vactosertib, a previously disclosed TGF-β inhibitor, in preclinical studies, as well as the immune recovery and therapeutic effects when combined with immune checkpoint inhibitors.
Vactosertib is a TGF-β signaling inhibitor that inhibits the function of transforming growth factor TGF-β, a major mechanism known to hinder the therapeutic effects of immune checkpoint inhibitors. It regulates the tumor microenvironment to help various anticancer drugs attack cancer cells and plays a role in inhibiting cancer proliferation and metastasis.
Hot Picks Today
At President Lee's Call to "Give Enough to Shock," Whistleblower Rewards Become a Real Lottery
- If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Lee Warns "Do Not Cross the Line" as Minister Steps In... Behind the Scenes of Defusing the Samsung Strike Crisis
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
MedPacto is conducting clinical trials on combination therapies of Vactosertib with existing anticancer drugs in multiple cancer types, including pancreatic cancer, non-small cell lung cancer, bladder cancer, and gastric cancer.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
